vTv Therapeutics (VTVT) Change in Accured Expenses (2014 - 2025)

vTv Therapeutics has disclosed Change in Accured Expenses across 12 years of filings, most recently posting -$3.2 million for Q4 2025.

• Change in Accured Expenses for Q4 2025 came in at -$3.2 million, down 170.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (up 139.36% YoY), and the FY2025 annual result was $1.5 million, up 129.34% from the prior year.
• Change in Accured Expenses came in at -$3.2 million for Q4 2025 at vTv Therapeutics, down from $4.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.9 million in Q3 2025 to a low of -$3.9 million in Q3 2024.
• The 5-year median for Change in Accured Expenses is -$42000.0 (2024), against an average of -$42421.1.
• Across the five-year window, Change in Accured Expenses sank 2143.41% in 2022 and soared 1876.19% in 2025, its largest moves.
• vTv Therapeutics' Change in Accured Expenses stood at $1.5 million in 2021, then declined by 3.21% to $1.4 million in 2022, then sank by 53.49% to $659000.0 in 2023, then slumped by 281.94% to -$1.2 million in 2024, then sank by 170.73% to -$3.2 million in 2025.
• The last three Change in Accured Expenses figures came in at -$3.2 million (Q4 2025), $4.9 million (Q3 2025), and $746000.0 (Q2 2025), per Business Quant data.